Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04154553

Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure

Sponsor: University Hospital, Basel, Switzerland

View on ClinicalTrials.gov

Summary

Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care. The primary objective is the compilation of case reports, where pharmacogenetic testing is applied to determine the hereditable component of the patient's susceptibility to experience therapy failure and/or adverse drug reactions. The experience with the compiled cases will be basis for the development of a reliable standard of procedure for pharmacogenetic testing in the community pharmacy. The cases will be supplemented with information on additional Parameters reported in the literature to affect efficacy or safety of the respective drug.

Key Details

Gender

All

Age Range

2 Years - Any

Study Type

OBSERVATIONAL

Enrollment

400

Start Date

2019-10-15

Completion Date

2026-08

Last Updated

2025-05-14

Healthy Volunteers

Yes

Interventions

DIAGNOSTIC_TEST

Buccal swab

Pharmacogenetic panel testing is conducted by Stratipharm with the DNA of the buccal swab. TaqMan® polymerase chain reaction is proceeded to express the genetic information. Stratipharm is a product offered by Humatrix Aktiengesellschaft (AG). It consists of a laboratory analysis of approximately 100 pharmacological relevant genetic variations (polymorphisms) in over 30 different genes, which code for transport proteins, metabolizing enzymes, or drug targets.

DIAGNOSTIC_TEST

EDTA Blood sample (4.9mL)

Genetic testing of potentially relevant genetic variants using the DNA extracted from the EDTA blood sample.

DIAGNOSTIC_TEST

Serum sample (7.5mL)

blood sample to determine the actual levels of the compound in patients on medication assumed to be associated to an observed ADR (phenotype).

OTHER

communication of test results

Certified study pharmacist evaluates and communicates clinically relevant test results to the subject and to the responsible physician

OTHER

unstructured interview

One and six months after the communication of test results, the study center will make a phone call to the patient for an unstructured interview in order to gather information about potential outcomes

Locations (1)

Department of Pharmaceutical Sciences, University Basel

Basel, Switzerland